I wrote about Louis Navellier’s “solar monopoly” pitch a little while ago, but there was a also a cancer-fighting stock teased in that ad… and a few folks have been asking about that second stock, so I’ll see what we can do to get the Thinkolator on the case. Here’s a bit of the ad: […]
Or perhaps a better title would have been, “Pruning during a forest fire.” As the markets go through wild swings (no, that’s not right — swings move both ways — I mean “wild drops”), I feel as I often do at times like these: That I wish I had more cash to invest. I’d never […]
This note should not be considered to indicate my opinions on any of the stocks herein, or to be any kind of market prognostication about the months ahead (I’m personally worried about the market this fall, but I rarely trade on such short term worries). But since I’ve promised to disclose my portfolio to you, […]
If you happen to follow any of the stocks I own, you might have noticed two big movers lately, in opposite directions — Exelixis moving up, and ABB Grain moving down. In my opinion, neither one has huge implications, but both of these moves are because the company is raising money for future projects. In […]
Comments
An excellent exegesis of excecrable Navellierian exaggeration. I also owned it way back then, and after losing some mone...
I bought $EXEL a few years ago for $11 and change left it alone unil they had a viable product, just sold it when it hit...
$EXEL Doc, thanks for your summation. If you expect failure in the HCC trial that's reason enough for me not to pull th...
I'll have a crack at it. It's hard to justify covering, and logging research hours poking into, companies where we see n...
$EXEL,$BMY Exelixis and Bristol-Myers are two companies that have gotten relatively scant attention here over the years...
$AUPH: My hometown is Melbourne, maybe I should go on a reconnaissance mission as an attaché-for the Gummune. Do you ne...
Ophad Hammer blog on $ESPR, $TRVN,$EXEL, $ARGL. Very long ESPR, long EXEL http://www.orf-blog.com/biotech-portfolio-u...
$EXEL #RCC $EXEL and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Thera...
Below is an interesting blog article - another affirmation and salutation to Dr. KSS's biotech vision: "2016 Biotech ...
$EXEL Don't want to steal your time - but do you have a quick opinion about exelixis and its recent mighty run? Haven...
$EXEL - From SA: http://seekingalpha.com/news/3187291-exelixis-cabometyx-superior-novartis-afinitor-extending-survival-k...
Thank you for the information. I do not own any $EXEL now, but did, and was wondering if would be a good repurchase. I...
Someone was asking about Exelixis in the context of its pursuing approval for cabozantinib for renal cell cancer. Keep i...
$EXEL My questions are How much would Cabozantinib add to the bottom line per share given that Novartis is in this ...
Expect heavy selling pressure on small cap bio in wake of today's $EXEL brouhaha. $EXEL will be down 50 per cent. Probab...